Drug
Mcla 117 Bispecific Antibody
Mcla 117 Bispecific Antibody: highest development phase Phase 1, developed by Merus. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Merus
Trials
| Drug | Phase | Indication |
|---|---|---|
| MCLA-117 bispecific antibody NCT03038230 | Phase 1 | Acute Myelogenous Leukemia |
Latest
No recent events.
Follow Mcla 117 Bispecific Antibody on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.